143 related articles for article (PubMed ID: 17551919)
21. O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines.
Johnson SP; Kamen BA; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 2007 Nov; 60(6):883-9. PubMed ID: 17333191
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of a folate-targeted rhaponticin conjugate.
Liang X; Sun Y; Zeng W; Liu L; Ma X; Zhao Y; Fan J
Bioorg Med Chem; 2013 Jan; 21(1):178-85. PubMed ID: 23177726
[TBL] [Abstract][Full Text] [Related]
23. The therapeutic efficiency of FP-PEA/TAM67 gene complexes via folate receptor-mediated endocytosis in a xenograft mice model.
Arote RB; Hwang SK; Lim HT; Kim TH; Jere D; Jiang HL; Kim YK; Cho MH; Cho CS
Biomaterials; 2010 Mar; 31(8):2435-45. PubMed ID: 20022105
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic.
Leamon CP; Reddy JA; Vlahov IR; Vetzel M; Parker N; Nicoson JS; Xu LC; Westrick E
Bioconjug Chem; 2005; 16(4):803-11. PubMed ID: 16029021
[TBL] [Abstract][Full Text] [Related]
25. Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent.
Reddy JA; Nelson M; Dircksen C; Vetzel M; Johnson T; Cross V; Westrick E; Qi L; Hahn S; Santhapuram HK; Parham G; Wang K; Vaughn JF; Felten A; Pugh M; Lu J; Klein P; Vlahov IR; Leamon CP
Sci Rep; 2020 Jul; 10(1):12772. PubMed ID: 32728172
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.
Lorusso PM; Edelman MJ; Bever SL; Forman KM; Pilat M; Quinn MF; Li J; Heath EI; Malburg LM; Klein PJ; Leamon CP; Messmann RA; Sausville EA
J Clin Oncol; 2012 Nov; 30(32):4011-6. PubMed ID: 23032618
[TBL] [Abstract][Full Text] [Related]
27. Increase of doxorubicin sensitivity for folate receptor positive cells when given as the prodrug N-(phenylacetyl) doxorubicin in combination with folate-conjugated PGA.
Zhang Q; Xiang G; Zhang Y; Yang K; Fan W; Lin J; Zeng F; Wu J
J Pharm Sci; 2006 Oct; 95(10):2266-75. PubMed ID: 16883559
[TBL] [Abstract][Full Text] [Related]
28. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide.
Vlahov IR; Santhapuram HK; Kleindl PJ; Howard SJ; Stanford KM; Leamon CP
Bioorg Med Chem Lett; 2006 Oct; 16(19):5093-6. PubMed ID: 16870437
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo evaluation of (99m)Tc-DO3A-EA-Folate for receptor-mediated targeting of folate positive tumors.
Mishra G; Hazari PP; Kumar N; Mishra AK
J Drug Target; 2011 Nov; 19(9):761-9. PubMed ID: 21425922
[TBL] [Abstract][Full Text] [Related]
30. Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.
Ambrosio AJ; Suzin D; Palmer EL; Penson RT
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):443-50. PubMed ID: 24742319
[TBL] [Abstract][Full Text] [Related]
31. Properties influencing the relative binding affinity of pteroate derivatives and drug conjugates thereof to the folate receptor.
Leamon CP; You F; Santhapuram HK; Fan M; Vlahov IR
Pharm Res; 2009 Jun; 26(6):1315-23. PubMed ID: 19189203
[TBL] [Abstract][Full Text] [Related]
32. The folate receptor as a rational therapeutic target for personalized cancer treatment.
Assaraf YG; Leamon CP; Reddy JA
Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
[TBL] [Abstract][Full Text] [Related]
33. Tumor-selective radiopharmaceutical targeting via receptor-mediated endocytosis of gallium-67-deferoxamine-folate.
Mathias CJ; Wang S; Lee RJ; Waters DJ; Low PS; Green MA
J Nucl Med; 1996 Jun; 37(6):1003-8. PubMed ID: 8683292
[TBL] [Abstract][Full Text] [Related]
34. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
[TBL] [Abstract][Full Text] [Related]
35. [Folate-poly-L-lysine-Gd-DTPA as MR contrast agent for tumor imaging via folate receptor-targeted delivery].
Yuan Z; Liu SY; Xiao XS; Zhong GR; Jiang QJ
Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(10):673-8. PubMed ID: 17553304
[TBL] [Abstract][Full Text] [Related]
36. [Folate receptor-mediated antitumor drugs].
Zhao J; Cao SL; Zheng XL; Zhao B
Yao Xue Xue Bao; 2009 Feb; 44(2):109-14. PubMed ID: 19408677
[TBL] [Abstract][Full Text] [Related]
37. Vintafolide: a novel targeted agent for epithelial ovarian cancer.
Graybill WS; Coleman RL
Future Oncol; 2014 Mar; 10(4):541-8. PubMed ID: 24754586
[TBL] [Abstract][Full Text] [Related]
38. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo.
Leamon CP; Cooper SR; Hardee GE
Bioconjug Chem; 2003; 14(4):738-47. PubMed ID: 12862426
[TBL] [Abstract][Full Text] [Related]
39. Effects of the antifolates pemetrexed and CB3717 on the tissue distribution of (99m)Tc-EC20 in xenografted and syngeneic tumor-bearing mice.
Müller C; Reddy JA; Leamon CP; Schibli R
Mol Pharm; 2010 Apr; 7(2):597-604. PubMed ID: 20199053
[TBL] [Abstract][Full Text] [Related]
40. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug.
Stevens PJ; Sekido M; Lee RJ
Pharm Res; 2004 Dec; 21(12):2153-7. PubMed ID: 15648245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
